Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$40.34M$40.34M+18.8% vs Q3 2016 Net Income-$17.79M-$17.79MN/M vs Q3 2016 EPS Diluted-$0.46-$0.46N/M vs Q3 2016 Operating Income-$10,608,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$5,817,000+26.7% Margins · derivedOperating margin-26.3%+33.7 pt vs Q3 2016
Net margin-44.1%+65.2 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end